Get started

Fusion

Fusion Finance almost reached bottomPrice is moving in the final sub wave 5 of the ending diagonal wave C highlighted. The higher degree wave count shows an elongated flat ABC correction. Instead of catching the falling knife, wait for the price to close above 253 for averaging. Price is showing strong bullish divergence with RSI and with declining volume activity, trend reversal is expected soon. Short term target is around 444 level. Long term target is around 1170 considering a reverse H&S pattern formation on it's way up. Do your own due diligence before taking any action. Peace!!
NSE:FUSIONLong
by Swastik24
FUSION MICRO FINANCE (Hidden Gem)Price bounced at key support zone highlighted in green and RSI is showing strong bullish divergence on both daily & weekly TF. A greater degree wave 3 has started. Good to buy at CMP for the following targets: Short term swing target @ 670 (40% ROI) Medium term positional target @ 940 (96% ROI) Long term positional target @ 1075 (125% ROI) Fundamentally, it is highly undervalued with strong sales growth and great financing margin. Net profit has increased 7 times in last 4 years. In the last 5 quarters, institutions have increased their shareholdings by 63% from 18.09% to 29.55%. Do your own due diligence before taking any action. Peace!!
NSE:FUSIONLong
by Swastik24
AstraZeneca Set to Buy Fusion Pharmaceuticals for $2 BillionIn a strategic move to bolster its oncology portfolio, AstraZeneca announced its acquisition of Fusion Pharmaceuticals Inc. ( NASDAQ:FUSN ) for a staggering $2 billion in cash. This bold step underscores AstraZeneca's commitment to pioneering next-generation cancer therapies. Fusion Pharma ( NASDAQ:FUSN ), a clinical-stage biopharmaceutical company, has been making waves with its innovative approach to cancer treatment. At the heart of their technology are "next-generation" radioconjugates (RCs), which deliver a radioactive payload directly to cancer cells with unparalleled precision. This novel modality has gained significant traction in recent years, offering renewed hope for patients battling various forms of cancer. The jewel in Fusion's crown is its leading candidate, FPI-2265, currently undergoing a mid-stage trial for metastatic castration-resistant prostate cancer. This promising therapy represents a beacon of hope for patients and clinicians alike, offering the potential for more effective and targeted treatment options. AstraZeneca's decision to invest in Fusion Pharma ( NASDAQ:FUSN ) speaks volumes about its strategic vision. By embracing cutting-edge technologies like radio conjugates, AstraZeneca is positioning itself at the forefront of the fight against cancer. Susan Galbraith, Executive Vice President of Oncology R&D at AstraZeneca, expressed enthusiasm about the acquisition, highlighting its potential to transform cancer care. Traditionally, cancer treatment has relied heavily on radiotherapy and chemotherapy. While these modalities have saved countless lives, they often come with significant side effects and limited efficacy. With the advent of radiocon jugates, there's newfound optimism in the field, offering the promise of more targeted and potent therapies. AstraZeneca's acquisition of Fusion Pharma ( NASDAQ:FUSN ) is not just a business transaction; it's a testament to the company's unwavering commitment to advancing the frontiers of medicine. By combining resources and expertise, AstraZeneca and Fusion Pharma ( NASDAQ:FUSN ) aim to accelerate the development of transformative therapies that could change the lives of millions affected by cancer. Moreover, AstraZeneca's recent acquisitions, including the $1.05 billion deal with Amolyt Pharma, underscore its dedication to addressing unmet medical needs across various therapeutic areas. This concerted effort to expand its rare disease and oncology portfolios signals a new era of innovation and progress for the company. Looking ahead, Fusion Pharma's ( NASDAQ:FUSN ) Phase 2/3 protocol alignment with the FDA for FPI-2265 sets the stage for a pivotal Phase 3 registrational trial slated to commence in 2025. This milestone represents a significant step forward in bringing this groundbreaking therapy to patients in need.
FLong
by DEXWireNews
1
TRUMP Victory-Calling all Hedge Funds - LMT to the Moon-FusionThis is mostly technical analysis based on projected world events. LMT is a great company period. When it comes to business, if APPL was run like LMT, APPL would be much better than what it is today. Why? 1) World conflict will intensify - and be dragged on. 2) Fusion reactor will be deploy-able around the continental US in 2020 ( thu this is a rough prediction as GT can not pinpoint the exact date just yet, the date will be a business model driven decision - 80%) Lockheed Martin is run like a well built machine, aside N. Fusion this company is developing A.I. that is not just impressive, but,.... . And other units are a prime example(like its biological) of how well this company is doing. TRUMP will increase spending with this corporation. To the moon Alice!
NYSE:LMTLong
by Marek99
5